232.75

0.31% 0.72

After Hours: 232.75

Insulet Corporation (PODD)

Overview News Price History Option Chain Financials Why PODD Down? Discussions Forecast

Insulet Corporation stock is traded at $232.75, with a volume of 530.74K. It is up +0.31% in the last 24 hours and up +14.79% over the past month. Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.

Previous Close:

$232.03

Open:

$232.68

24h Volume:

530.74K

Relative Volume:

0.75

Market Cap:

$16.14B

Revenue:

$1.87B

Net Income/Loss:

$395.30M

P/E Ratio:

136.11

EPS:

1.71

Net Cash Flow:

$182.40M

1W Performance:

-2.60%

1M Performance:

+14.79%

6M Performance:

+35.79%

1Y Performance:

+45.93%

1-Day Range:

$229.32

$233.44

1-Week Range:

$229.32

$242.69

52-Week Range:

$125.82

$243.98

Insulet Corporation Stock (PODD) Company Profile

Name

Insulet Corporation

Sector

Healthcare (1190)

Industry

Medical Devices (154)

Phone

978-600-7000

Address

100 NAGOG PARK, ACTON, MA

Employee

3,000

Twitter

@insulet_uk

Next Earnings Date

2024-08-08

Latest SEC Filings

PODD's Discussions on Twitter

Insulet Corporation Stock (PODD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-21-23	Upgrade	Robert W. Baird	Neutral → Outperform
Dec-04-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Oct-02-23	Upgrade	Jefferies	Hold → Buy
Aug-21-23	Upgrade	Citigroup	Neutral → Buy
Aug-21-23	Downgrade	Robert W. Baird	Outperform → Neutral
May-30-23	Resumed	Morgan Stanley	Equal-Weight
Jan-26-23	Initiated	Wolfe Research	Peer Perform
Nov-04-22	Upgrade	Piper Sandler	Neutral → Overweight
Oct-18-22	Initiated	Barclays	Equal Weight
Oct-12-22	Initiated	Jefferies	Hold
Jul-11-22	Downgrade	Citigroup	Buy → Neutral
Mar-02-22	Resumed	BofA Securities	Buy
Feb-03-22	Upgrade	BTIG Research	Neutral → Buy
Feb-02-22	Upgrade	UBS	Neutral → Buy
Jan-31-22	Upgrade	Oppenheimer	Perform → Outperform
Jul-21-21	Resumed	Cowen	Outperform
May-25-21	Initiated	Barclays	Overweight
Apr-01-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Mar-19-21	Upgrade	Canaccord Genuity	Hold → Buy
Jan-29-21	Downgrade	Piper Sandler	Overweight → Neutral
Dec-16-20	Downgrade	Citigroup	Buy → Neutral
Jul-28-20	Initiated	Wells Fargo	Overweight
Apr-24-20	Downgrade	SVB Leerink	Outperform → Mkt Perform
Apr-03-20	Initiated	BofA/Merrill	Neutral
Mar-31-20	Downgrade	Berenberg	Buy → Hold
Mar-05-20	Initiated	Citigroup	Buy
Dec-10-19	Initiated	CFRA	Sell
Oct-23-19	Initiated	Stifel	Hold
Oct-18-19	Downgrade	Canaccord Genuity	Buy → Hold
Oct-14-19	Downgrade	BTIG Research	Buy → Neutral
Oct-04-19	Downgrade	UBS	Buy → Neutral
Oct-03-19	Downgrade	Guggenheim	Buy → Neutral
Aug-06-19	Upgrade	JP Morgan	Neutral → Overweight
Jun-10-19	Downgrade	Northland Capital	Outperform → Market Perform
May-06-19	Upgrade	BTIG Research	Neutral → Buy
Apr-20-18	Initiated	Berenberg	Buy
Feb-22-18	Reiterated	Barclays	Overweight
Jan-08-18	Upgrade	Raymond James	Mkt Perform → Outperform
Nov-03-17	Upgrade	Canaccord Genuity	Hold → Buy
Sep-15-17	Initiated	Barclays	Overweight

View All

Insulet Corporation Stock (PODD) Latest News

06:58 AM

Insulet to Announce Third Quarter 2024 Financial Results on November 7, 2024 - BioSpace

06:58 AM

06:00 AM

Insulet to Announce Third Quarter 2024 Financial Results on November 7, 2024 - StockTitan

06:00 AM

05:40 AM

Insulet Co. (NASDAQ:PODD) Stock Position Cut by Toronto Dominion Bank - MarketBeat

05:40 AM

Sep 29, 2024

Insulet Co. (NASDAQ:PODD) Holdings Boosted by BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp - MarketBeat

Sep 29, 2024

Sep 28, 2024

Insulet Co. (NASDAQ:PODD) Stock Position Lifted by Beck Bode LLC - MarketBeat

Sep 28, 2024

Sep 27, 2024

Insulet Co. (NASDAQ:PODD) Holdings Cut by Axa S.A. - MarketBeat

Sep 27, 2024

Sep 26, 2024

Deerfield Management Company L.P. Series C Buys 2,372 Shares of Insulet Co. (NASDAQ:PODD) - MarketBeat

Sep 26, 2024

Insulet shares target raised on robust diabetes survey results By Investing.com - Investing.com Australia

Sep 26, 2024

Sep 25, 2024

Insulet shares target raised on robust diabetes survey results By Investing.com - Investing.com South Africa

Sep 25, 2024

Insulet shares target raised on robust diabetes survey results By Investing.com - Investing.com Canada

Sep 25, 2024

Insulet shares target raised on robust diabetes survey results - Investing.com

Sep 25, 2024

Company’s Banking Stock: Dissecting a -53.71% Quarterly Revenue Decline Amid Growth - The InvestChronicle

Sep 25, 2024

Insulet (NASDAQ:PODD) Price Target Increased to $269.00 by Analysts at Canaccord Genuity Group - MarketBeat

Sep 25, 2024

Insulet shares target raised on robust diabetes survey results By Investing.com - Investing.com UK

Sep 25, 2024

Public Employees Retirement Association of Colorado Sells 230 Shares of Insulet Co. (NASDAQ:PODD) - Defense World

Sep 25, 2024

Marshall Wace LLP Purchases Shares of 495,431 Insulet Co. (NASDAQ:PODD) - MarketBeat

Sep 25, 2024

Sep 24, 2024